Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals (NQ: IONS )

49.64 USD +0.94 (+1.93%)
Streaming Delayed Price Updated: 10:36 AM EDT, Sep 28, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 115,886
Open 49.32
Bid (Size) 49.52 (2)
Ask (Size) 49.60 (2)
Prev. Close 48.70
Today's Range 48.97 - 49.91
52wk Range 39.32 - 66.22
Shares Outstanding 125,520,380
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Ionis to present at upcoming virtual investor conferences
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following virtual investor conferences: 
From PR Newswire
New England Journal of Medicine publishes study results evaluating Ionis antisense therapy in treatment of patients with hereditary angioedema
- Compassionate-use study supports continued development of IONIS-PKK-LRx as an experimental treatment to reduce acute attacks of hereditary angioedema 
From PR Newswire

Performance

YTD
-18.48%
-18.48%
1 Month
-5.97%
-5.97%
3 Month
-16.43%
-16.43%
6 Month
+2.97%
+2.97%
1 Year
-17.14%
-17.14%

More News

Read More
(AKCA) Alert: Johnson Fistel Investigates Proposed Sale of Akcea Therapeutics; Is $18.15 a Fair Price?
From PR Newswire
SHAREHOLDER ALERT: WeissLaw LLP Investigates Akcea Therapeutics, Inc.
From PR Newswire
AKCEA THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of AKCA and Encourages Investors to Contact the Firm
From GlobeNewswire News Releases
Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics
From PR Newswire
Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020
From PR Newswire
Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020
From PR Newswire
Ionis Pharmaceuticals to hold cardio-renal franchise webcast
From PR Newswire
eToro Market Movers Healthcare Stocks: $IONS $BAYN.DE $CHR.CO
Tags The Market Signal
From The Market Signal
Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.